US approves Sanofi, Regeneron arthritis drughealthmedicinetMay 23, 2017news Top promoted drugs are less likely than top selling and top prescribed drugs to be effective, safe, affordable, novel, and represent a genuine advance in treating a disease, argue US researchers in The BMJ today. Related posts: HMN 2025: How FDA approves SetPoint neuroimmune modulation device for rheumatoid arthritis HMN 2025: How FDA approves Tremfya for pediatric plaque psoriasis, active psoriatic arthritis HMN 2025: How Self-guided online program improves quality of life in rheumatoid arthritis, psoriatic arthritis and lupus Previous Post Pediatricians can play a pivotal role in reducing pediatric firearm-related injuries Next Post Researchers demonstrate multicolor 3D imaging of live mouse using compact Compton camera
